Редактирование: HEXA

Beta-hexosaminidase subunit alpha precursor (EC 3.2.1.52) (Beta-N-acetylhexosaminidase subunit alpha) (Hexosaminidase subunit A) (N-acetyl-beta-glucosaminidase subunit alpha)

==Publications==

{{medline-entry
|title=The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish [[HEXA]] immune study.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/22415616
|abstract=The Swedish OCTO and NONA immune longitudinal studies were able to identify and confirm an immune risk profile (IRP) predictive of an increased 2-year mortality in very old individuals, 86-94 years of age. The IRP, was associated with persistent cytomegalovirus infection and characterized by inverted CD4/CD8 ratio and related to expansion of terminally differentiated effector memory T cells (TEMRA phenotype). In the present [[HEXA]] immune longitudinal study, we have examined a younger group of elderly individuals (n = 424, 66 years of age) in a population-based sample in the community of Jönköping, Sweden, to examine the relevance of findings previously demonstrated in the very old. Immunological monitoring that was conducted included T cell subsets and CMV-IgG and CMV-IgM serology. The result showed a prevalence of 15 % of individuals with an inverted CD4/CD8 ratio, which was associated with seropositivity to cytomegalovirus and increases in the level of TEMRA cells. The proportion of individuals with an inverted CD4/CD8 ratio was significantly higher in men whereas the numbers of CD3 CD4  cells were significantly higher in women. In conclusion, these findings are very similar to those previously found by us in the Swedish longitudinal studies, suggesting that an immune profile previously identified in the very old also exists in the present sample of hexagenerians. Therefore, it will be important to examine clinical parameters, including morbidity and mortality, to assess whether the immune profile also is a risk profile associated with higher mortality in this sample of hexagenerians.
|mesh-terms=* Aged
* Aged, 80 and over
* Aging
* CD4-CD8 Ratio
* CD4-Positive T-Lymphocytes
* CD8-Positive T-Lymphocytes
* Cytomegalovirus
* Cytomegalovirus Infections
* Female
* Humans
* Immunity, Cellular
* Male
* Morbidity
* Retrospective Studies
* Sweden

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636392
}}
{{medline-entry
|title=Gene expression profiling suggests a pathological role of human bone marrow-derived mesenchymal stem cells in aging-related skeletal diseases.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/21808097
|abstract=Aging is associated with bone loss and degenerative joint diseases, in which the aging of bone marrow-derived mesenchymal stem cell (bmMSC)[1] may play an important role. In this study, we analyzed the gene expression profiles of bmMSC from 14 donors between 36 and 74 years old, and obtained age-associated genes (in the background of osteoarthritis) and osteoarthritis-associated genes (in the background of old age). Pathway analysis of these genes suggests that alterations in glycobiology might play an important role in the aging of human bmMSC. On the other hand, antigen presentation and signaling of immune cells were the top pathways enriched by osteoarthritis-associated genes, suggesting that alteration in immunology of bmMSC might be involved in the pathogenesis of osteoarthritis. Most intriguingly, we found significant age-associated differential expression of [[HEXA]], [[HEXB]], [[CTSK]], [[SULF1]], [[ADAMTS5]], [[SPP1]], [[COL8A2]], [[GPNMB]], [[TNFAIP6]], and RPL29; those genes have been implicated in the bone loss and the pathology of osteoporosis and osteoarthritis in aging. Collectively, our results suggest a pathological role of bmMSC in aging-related skeletal diseases, and suggest the possibility that alteration in the immunology of bmMSC might also play an important role in the etiology of adult-onset osteoarthritis.
|mesh-terms=* Adult
* Aged
* Aging
* Animals
* Bone Marrow Cells
* Carbohydrate Conformation
* Carbohydrate Sequence
* Female
* Gene Expression Profiling
* Humans
* Joint Diseases
* Male
* Mesenchymal Stem Cells
* Middle Aged
* Molecular Sequence Data
* Oligonucleotide Array Sequence Analysis
* Osteoarthritis
* Polysaccharides
* Rats

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181167
}}
{{medline-entry
|title=Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/8921832
|abstract=We have reported Hexarelin ([[HEXA]]), an analog of growth hormone-releasing peptide 6 (GHRP-6), potently stimulates growth hormone (GH) secretion in infant and adult rats. This study was undertaken to further investigate Hexarelin's mechanisms of action. In 10-day-old pups, treatments with [[HEXA]] (80 micrograms/kg, b.i.d.) for 3-10 days significantly enhanced, in a time-related fashion, the GH response to an acute [[HEXA]] challenge. Qualitatively similar effects were elicited in pups passively immunized against growth hormone-releasing hormone ([[GHRH]]) from birth. In adult male rats, a 5-day pretreatment with [[HEXA]] (150 micrograms/kg, b.i.d.) did not enhance the effect of the acute challenge, and the same pattern was present after a 5-day pretreatment in male rats with surgical ablation of the mediobasal hypothalamus (MBH-ablated rats). In addition, in adult sham-operated rats, Hexarelin (300 micrograms/kg, i.v.) induced a GH response greater (p < 0.05) than that induced by [[GHRH]] (2 micrograms/kg, i.v.). However, in MBH-ablated rats 7 days after surgery, [[GHRH]] was significantly (p < 0.05) more effective than [[HEXA]], and 30 days after surgery [[HEXA]] and [[GHRH]] evoked similar rises of plasma GH. Finally, the in vitro Hexarelin (10(-6) mol/l) effect was transient while [[GHRH]] (10(-8) mol/l) induced a longer lasting and greater GH release. Three different mechanisms, not mutually exclusive, are postulated for Hexarelin stimulation of GH secretion in vivo: a direct action on the pituitary, though of minor relevance; an indirect action that involves release of [[GHRH]], of relevance only in adult rats; and an action through the release of a still unknown hypothalamic "factor", which in infant and adult rats elicits GH release acting sinergistically with [[GHRH]].
|mesh-terms=* Aging
* Animals
* Animals, Newborn
* Female
* Growth Hormone
* Male
* Oligopeptides
* Pituitary Gland
* Rats
* Rats, Sprague-Dawley
* Time Factors

|full-text-url=https://sci-hub.do/10.1530/eje.0.1350481
}}